The Stop TB Partnership and Bamboo Capital Partners, an impact investing platform, signed a partnership agreement to support small- and medium-enterprises and start-ups, particularly from TB affected countries, developing impactful health technologies for TB, COVID-19, and TB co-morbidities.
The HEAL fund, a US$ 75 million blended finance investment vehicle, will leverage US$ 15 million in catalytic funding to incentivize and unlock US$ 60 million of private institutional investment capital. This fund will focus on providing early-stage financing for innovations that will transform health systems by catalyzing community- and home-based care for all people, including the most marginalized communities.
As part of this partnership, in addition to providing capital to innovators to further commercialize their solutions and unlike other impact investment funds, the Stop TB Partnership’s Accelerator for Impact (a4i) platform, with support from the Country & Community Support for Impact team and TB REACH initiative, will provide fit-for-purpose product launch/technical support for critical downstream activities to optimize and accelerate the roll-out of these impactful health technologies.